Diffusely Increased Bone Marrow Uptake on DOTATATE PET/CT Due to PRRT-related Myelodysplasia Syndrome.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 40830914.
- Also identified by DOI 10.1097/RLU.0000000000006095.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We report an unusual imaging finding on DOTATATE PET/CT in a patient with prior 177Lu-DOTATATE treatment for metastatic small bowel neuroendocrine tumor. Five years post-treatment follow-up DOTATATE PET/CT for fatigue and back pain showed new diffusely increased bone marrow uptake in addition to focal uptake corresponding to known metastases. Faint/mild bone marrow uptake of DOTATATE can be seen due to the presence of SST-2 receptor on CD-34 hematopoietic progenitor cells in the marrow, but diffusely increased marrow uptake, as in this case, was not deemed physiologic and was concerning for marrow pathology. Subsequent bone marrow biopsy confirmed therapy-related myelodysplastic syndrome (t-MDS).
Medical subject headings
- Bone Marrow
- Myelodysplastic Syndromes
- Octreotide
- Organometallic Compounds
- Positron Emission Tomography Computed Tomography